Flamel Technologies S.A. (ADR) (NASDAQ:FLML) reported ($0.94) EPS for the quarteron last Monday, missing the Thomson Reuters consensus estimate of ($0.15) by $0.79, Stock Ratings Network.com reports. The company had revenue of $9.20 million for the quarter, compared to the consensus estimate of $7.47 million. During the same quarter in the prior year, the company posted ($0.35) earnings per share. Flamel Technologies S.A. (ADR) (NASDAQ:FLML) weekly performance is -8.36%. On last trading day company shares ended up $10.41. Analysts mean target price for the company is $20.95. Flamel Technologies S.A. (ADR) (NASDAQ:FLML) distance from 50-day simple moving average (SMA50) is -13.04%.
Equities research analysts at Maxim Group lowered their target price on shares of Intellipharmaceutics Intl Inc (USA) (NASDAQ:IPCI) from $9.00 to $7.00 in a research note issued to investors on Thursday, StockRatingsNetwork reports. The firm currently has a “buy” rating on the stock. Maxim Group’s price objective suggests a potential upside of 72.84% from the company’s current price. IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) shares fell -0.26% in last trading session and ended the day on $3.81. Its return on assets is -139.80%. IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) quarterly performance is -5.22%.
Petmed Express, Inc. (NASDAQ:PETS) reported Q4 EPS of $0.23, $0.01 better than the analyst estimate of $0.22. Revenue for the quarter came in at $48.6 million versus the consensus estimate of $55.02 million. Petmed Express Inc (NASDAQ:PETS) shares moved up 1.99% in last trading session and was closed at $13.35, while trading in range of $13.01 – $13.36. Petmed Express Inc (NASDAQ:PETS) year to date (YTD) performance is -17.64%.
pSivida Corp. (NASDAQ:PSDV) a leader in the development of sustained release, drug delivery products for treating eye diseases, announced financial results for its third quarter ended March 31, 2014. Net loss for the quarter ended March 31, 2014 was $2.2 million, or $0.08 per share, compared to a net loss of $2.8 million, or $0.12 per share, for the prior year quarter. The reduced net loss in the third quarter of fiscal 2014 primarily reflected the recognition of revenues in the fiscal 2014 third quarter noted above, partially offset by costs in the quarter associated with the Phase III clinical trial of Medidur for posterior uveitis, which had not commenced in last year’s third quarter. pSivida Corp. (NASDAQ:PSDV) ended the last trading day at $3.65 . Company weekly volatility is calculated as 7.17% and price to cash ratio as 5.01. pSivida Corp. (NASDAQ:PSDV) showed a positive weekly performance of 4.58%.
Panasonic Corporation (ADR) (OTCMKTS:PCRFY) projected about 18 percent growth when it came to capital investment compared to 2013. The bulk of this investment will be given to automobile related businesses like lithium ion batteries. The company has recently given its consent to participate in construction of the Tesla Motor Inc’s (NASDAQ: TSLA) US battery manufacturing unit. Panasonic Corporation (ADR) (OTCMKTS:PCRFY) on last trading day company shares ended up $10.60.